Endocrine Abstracts

Objective: To evaluate the results of laparoscopic adrenalectomy in our institutions.Methods: Prospectively collected data from 2000 to 2007.Results: During the 8-year study period, 160 laparoscopic adrenalectomies were performed in 150 patients. Mean age was 49.8 years (female: 60.7%). Twenty-seven patients (18%) had previous open abdominal operations. There were 10 bilateral (6.6%) for Cushing’s disease, 64 right (42.7%) and...

Objective: To evaluate the main clinical characteristics and the obstetrical results of perinatal morbi-mortality of women with gestacional diabetes in our Service.Material and method: We made a descriptive study of 83 gestational diabetes patients which became a pursuit coordinated between the services of Endocrinology and Gynecology. The following main aspects were analyzed: age, toxic habits, BMI pre-gestational, first pregnancy or not, previous antec...

Objectives: To verify the results of the insulin treatment intensification in the control of Diabetes Mellitus type 1 and 2 (DM1 and DM2).Methodology: Of 100 diabetic patients (30% DM1 and 70%DM2) derived to Day Diabetes Hospital (DDH) by glycemic decompensation during year 2007 were studied, 45% women and 55% men (we excluded the debut). The average age of the patients was of 35.1 years in DM1 and 64.4 years in DM2. The Hba1c in the first visit and to t...

Background and aims: CXC chemokine ligand 10 (CXCL10) also known as chemokine interferon γ inducible protein (IP-10) is a CXCR3 chemokine belongs to a group of structurally related molecules, that induce the chemotaxis of diverse leukocyte subtypes including activated T-helper 1 lymphocytes, natural killer cells and monocytes. In patients with Hashimoto’s thyroiditis, type 1 diabetes mellitus and Graves’ disease high levels of CXCL10 ligand in serum have been fo...

Objectives: To evaluate satisfaction with treatment in diabetic patients under therapy with inhaled insulin (exubera).Material and methods: Thirty-seven diabetic patients were evaluated, 27DM1 (75%) and 9DM2 (25%) that initiated treatment with Insulin inhaled (EXUBERA) between August and October 2007. Twenty-five men (69.4%) and 11 women (30.56%), between 18 and 71 years old (38.4±16.4) and with a time of evolution of diabetes between 0 and 47 years...

Objective: To study the improvement of metabolic control and patients satisfaction with glucose continuous monitoring systems (Guardian real time).Material and method: Fifteen DM1 patients studied (age: 33.8±13.40, years of evolution: 17.06±11.32) in intensive treatment (5 multidoses, 10 insulin pump) which were made one 4 days long blind monitoring Period 1 (blind period) with sensor CGMS Gold. Next another monitoring was made with a real time...

Objectives: To value the quality of life improvement and metabolic control in patients with DM1 in the 2 first years of treatment with insulin pump therapy.Material and methods: We studied 33 DM1 patients, 16 men (48.5%) and 17 women (51.5%), with average age of 34.2±12.2 and 16.3±10.21 years of disease. Pump indication was hypoglycemia in 10 (30.3%), badly metabolic control in 14 (42.4%), pregnancy in 5 (15.2%) and glycemic inestability in 4 (...

Objectives: To check possible advantages of ambulatory blood pressure monitoring (ABPM) in diagnosis and disease control respect to blood pressure conventional measurement ways.Also to study the circadian rhythm of each patient to detect higher cardiovascular risk situations.Material and methods: One hundred and nine patients were included in this study: 44% male, 56% female. ABPM were indicated in four different situations: hypert...

Introduction: Although involved in feeding and weight homeostasis, stimulation of pituitary GH secretion is the best established action of stomach-produced hormone ghrelin. However, its role in regulation of GH secretion is not yet clear. Some evidence indicates that circulating concentrations of GH and/or IGF-I could influence ghrelin levels. The pathophysiology of ghrelin secretion in acromegaly (specially aftar an oral glucose tolerance test (OGTT) is unclear.<p class="...

Central treatment with ghrelin increases body weight and fat accumulation. Here we explore the pharmacological effect of a combined central (ICV) infusion of ghrelin (0.3 nmol/day) and a recently developed ghrelin receptor (GHS-R1A) antagonist (JMV2959, 100 nmol/day) on food intake and body composition. The effect of ghrelin infusion for 14 days to increase body weight (20.7±0.9% vs 34.3±3.1%, saline vs ghrelin, P<0.001) was blocked by co-infusion with JMV...